Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of early-stage HER2+ BC and for metastatic BC (Arteaga et al., 2012; Mitri et al., 2012). This evidence concerns the gene ERBB2 and breast cancer.